Lake Zurich-based Fresenius Kabi Thursday announced the immediate availability in the U.S. of Stimufend, a drug similar to Neulasta, for use in patients at risk for febrile neutropenia, a common side effect of many anti-cancer medications.
Related posts
-
‘She’s my inspiration’: Soon-to-be 100-year-old still woman walks over three miles a day at The Centre of Elgin
Soon-to-be 100-year-old Betty McKeown was celebrated during a party at The Centre of Elgin on Thursday.... -
Buffalo Grove DePaul student speaks out about antisemitic campus attack
A Stevenson High School graduate and DePaul University student spoke out about a campus antisemitic attack. -
Buffalo Grove DePaul student speaks out about antisemitic campus attack
A Stevenson High School graduate and DePaul University student spoke out about a campus antisemitic attack.